Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.

Immunoglobulin G (IgG) replacement therapy is the standard of care for patients with primary immunodeficiencies with antibody deficiencies. Intravenous (IVIG), subcutaneous (SCIG), and hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) therapies differ in their pharmacokinetic (PK) profiles, administration routes, and dosing regimens. Information on use of subcutaneous therapy in IgG treatment-naive patients is limited.

Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.

Purpose: To assess the pharmacokinetics (PK) of subcutaneous immunoglobulin (SCIG) and hyaluronidase-facilitated SCIG (fSCIG) therapy across body mass index (BMI) and age categories in patients with primary immunodeficiency diseases (PIDD) previously treated with intravenous immunoglobulin (IVIG).

Methods: Using our previously published integrated population PK model based on data from eight clinical trials, simulations were conducted to examine the effects of BMI and age on serum immunoglobulin G (IgG) PK after administration of SCIG 0.15 g/kg weekly or fSCIG 0.

Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies.

Plasma-derived immunoglobulin G (IgG) replacement therapy represents the current standard of care for patients with primary or secondary antibody deficiencies, and includes intravenous (IVIG), subcutaneous (SCIG) and facilitated subcutaneous (fSCIG) immunoglobulin products. A holistic understanding of the pharmacokinetics (PK) of IgG for these therapies is key to optimizing their clinical use. We developed an integrated population PK model using non-linear mixed-effects modeling based on data from eight clinical trials (each ≥ 1 year duration; n = 384 patients), which simultaneously characterized IgG PK profiles of IVIG, SCIG or fSCIG in patients with primary immunodeficiencies and identified covariate effects.

Off camera.

Wearing body cameras at work is a terrible idea, especially in settings where establishing a trusting therapeutic relationship is vital (readers' panel, 14 June).

Shetland is where it's at.

There are so many challenges facing nurses and healthcare. From funding cuts to public health, the picture is dishearteningly complex. No wonder many would be tempted to disappear to a remote island.

A final reflection on my time as a nursing student.

In his final Student Column, Ed Freshwater looks back over the 3 years of his degree considering the things that went well, and the things he might have done differently.

Saying the wrong thing.

Ed Freshwater discusses the perils of social media and the boundaries that separate compassion and professionalism. Whatever you do, he says, never add patients as friends on Facebook!

Students: you are the future of nursing.

Now that his BSc in Mental Health Nursing is drawing to a close, Ed Freshwater considers his options, from professional development to a Master's degree.

Keeping an eye on things.

Whether you're steering clear of buses, watching your children play, or measuring the weight of your patients, there's no substitute for the power of observation, writes Ed Freshwater.